Ignite Creation Date:
2025-12-25 @ 4:25 AM
Ignite Modification Date:
2026-03-03 @ 9:16 PM
Study NCT ID:
NCT03626220
Status:
COMPLETED
Last Update Posted:
2025-01-20
First Post:
2018-08-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Acupuncture on Chemotherapy-induced Peripheral Neuropathy
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D015670', 'term': 'Acupuncture Therapy'}], 'ancestors': [{'id': 'D000529', 'term': 'Complementary Therapies'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'chenchinh2013@gmail.com', 'phone': '886-6-3553111', 'title': 'Dr. Chien-Chen Huang', 'phoneExt': '2231', 'organization': 'An Nan Hospital, China Medical University, Tainan, Taiwan'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'A total of nine weeks from the start of the study to the end of the study', 'eventGroups': [{'id': 'EG000', 'title': 'The Acupuncture Group', 'description': 'Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), and Shenmen(HT7) for upper limbs. For palm numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), and Zusanli(ST36) for lower limbs. For the acupuncture points, Taixi(KI3) and Yongquan(K1) should be added for foot numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .\n\nacupuncture: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi\'s Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, LTD., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 0, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'The Controlled Group', 'description': 'Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.\n\nacupuncture: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi\'s Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, LTD., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 0, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'The Average Pain Severity in the Brief Pain Inventory-Short Form(BPI-SF)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'The Acupuncture Group', 'description': 'Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), or Shenmen(HT7) for upper limbs. For plantar numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), or Zusanli(ST36) for lower limbs. If severe numbness occurred, Taixi(KI3) or Yongquan(K1) should be added for feet numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .'}, {'id': 'OG001', 'title': 'The Controlled Group', 'description': 'Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.10', 'spread': '2.33', 'groupId': 'OG000'}, {'value': '3.10', 'spread': '1.79', 'groupId': 'OG001'}]}]}, {'title': 'Week 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.72', 'spread': '1.48', 'groupId': 'OG000'}, {'value': '3.50', 'spread': '2.27', 'groupId': 'OG001'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.63', 'spread': '0.92', 'groupId': 'OG000'}, {'value': '2.78', 'spread': '2.82', 'groupId': 'OG001'}]}]}, {'title': 'Week 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.88', 'spread': '1.13', 'groupId': 'OG000'}, {'value': '2.70', 'spread': '2.00', 'groupId': 'OG001'}]}]}, {'title': 'Changes at week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.63', 'spread': '1.85', 'groupId': 'OG000'}, {'value': '-0.11', 'spread': '2.71', 'groupId': 'OG001'}]}]}, {'title': 'Changes at week 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.38', 'spread': '2.39', 'groupId': 'OG000'}, {'value': '-0.40', 'spread': '2.07', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'We measured the average pain severity 4 times within 9 weeks [at baseline (before the first treatment) and week 3, week 6, and week 9 during the protocol].', 'description': 'The average pain severity was chosen as the primary assessment as neuropathy symptoms based on its ability to detect neuropathic pain in cancer patients, as well as its use to assess CIPN symptoms in other controlled clinical trials.The BPI-SF assesses pain when responding to the questionnaire (right now) and at its worst, least, and average pain severity in the last 24 h. The items range from 0 to 10 (0 = no pain; 10 = worst pain). The higher the pain severity scores, the worse the degree of pain experienced by the patient. We analyzed the data (1) within group analysis: compared the data at week 6 with baseline, and the data at week 9 with baseline from each group. (2) between group analysis: compared the acupuncture group and sham acupuncture group at week 6 and week 9. (3) the between group differences of the changes from week 6 to baseline and from week 9 to baseline.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': '* In the acupuncture group, one subject withdrew from the trial because of needle phobia after the third week of treatment, and another subject withdrew from the trial because of cellulitis in the radiation treatment site after completing the sixth week of treatment\n* In the placebo group, one subject did not record the scoring result after completing the sixth week of acupuncture treatment because of the omission to fill in this scale'}, {'type': 'SECONDARY', 'title': 'Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group- Neurotoxicity(FACT/GOG-NTX)-13', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'The Acupuncture Group', 'description': 'Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), or Shenmen(HT7) for upper limbs. For plantar numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), or Zusanli(ST36) for lower limbs. If severe numbness occurred, Taixi(KI3) or Yongquan(K1) should be added for feet numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .'}, {'id': 'OG001', 'title': 'The Controlled Group', 'description': 'Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.'}], 'classes': [{'title': 'NtxS-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '37.60', 'spread': '6.08', 'groupId': 'OG000'}, {'value': '33.90', 'spread': '7.87', 'groupId': 'OG001'}]}]}, {'title': 'NtxS-week 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '37.89', 'spread': '6.01', 'groupId': 'OG000'}, {'value': '33.62', 'spread': '6.52', 'groupId': 'OG001'}]}]}, {'title': 'NtxS-week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '41.00', 'spread': '6.72', 'groupId': 'OG000'}, {'value': '36.44', 'spread': '8.71', 'groupId': 'OG001'}]}]}, {'title': 'NtxS-week 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '40.88', 'spread': '7.72', 'groupId': 'OG000'}, {'value': '35.90', 'spread': '5.92', 'groupId': 'OG001'}]}]}, {'title': 'NtxS-Changes at week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.63', 'spread': '5.07', 'groupId': 'OG000'}, {'value': '1.56', 'spread': '7.55', 'groupId': 'OG001'}]}]}, {'title': 'NtxS-Changes at wee 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.50', 'spread': '4.90', 'groupId': 'OG000'}, {'value': '2.00', 'spread': '6.96', 'groupId': 'OG001'}]}]}, {'title': 'TOI-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '76.60', 'spread': '14.74', 'groupId': 'OG000'}, {'value': '67.80', 'spread': '15.25', 'groupId': 'OG001'}]}]}, {'title': 'TOI-week 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '77.04', 'spread': '16.03', 'groupId': 'OG000'}, {'value': '69.57', 'spread': '13.39', 'groupId': 'OG001'}]}]}, {'title': 'TOI-week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '81.75', 'spread': '19.03', 'groupId': 'OG000'}, {'value': '73.44', 'spread': '16.54', 'groupId': 'OG001'}]}]}, {'title': 'TOI-week 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '80.42', 'spread': '20.58', 'groupId': 'OG000'}, {'value': '74.60', 'spread': '11.91', 'groupId': 'OG001'}]}]}, {'title': 'TOI-changes at week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.63', 'spread': '7.41', 'groupId': 'OG000'}, {'value': '3.00', 'spread': '14.34', 'groupId': 'OG001'}]}]}, {'title': 'TOI-changes at week 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.29', 'spread': '6.31', 'groupId': 'OG000'}, {'value': '6.80', 'spread': '12.62', 'groupId': 'OG001'}]}]}, {'title': 'FACT-G score-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '79.70', 'spread': '16.35', 'groupId': 'OG000'}, {'value': '69.73', 'spread': '14.19', 'groupId': 'OG001'}]}]}, {'title': 'FACT-G score-week 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '77.96', 'spread': '20.02', 'groupId': 'OG000'}, {'value': '73.20', 'spread': '15.95', 'groupId': 'OG001'}]}]}, {'title': 'FACT-G score-week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '80.08', 'spread': '19.80', 'groupId': 'OG000'}, {'value': '73.49', 'spread': '16.16', 'groupId': 'OG001'}]}]}, {'title': 'FACT-G score-week 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '77.54', 'spread': '21.55', 'groupId': 'OG000'}, {'value': '77.73', 'spread': '11.10', 'groupId': 'OG001'}]}]}, {'title': 'FACT-G score-changes at week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.06', 'spread': '2.89', 'groupId': 'OG000'}, {'value': '1.66', 'spread': '12.94', 'groupId': 'OG001'}]}]}, {'title': 'FACT-G score-changes at week 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.48', 'spread': '5.51', 'groupId': 'OG000'}, {'value': '8', 'spread': '10.31', 'groupId': 'OG001'}]}]}, {'title': 'FACT/GOG-Ntx total score-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '117.30', 'spread': '20.56', 'groupId': 'OG000'}, {'value': '103.63', 'spread': '19.75', 'groupId': 'OG001'}]}]}, {'title': 'FACT/GOG-Ntx total score-week 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '115.85', 'spread': '23.80', 'groupId': 'OG000'}, {'value': '106.82', 'spread': '18.34', 'groupId': 'OG001'}]}]}, {'title': 'FACT/GOG-Ntx total score-week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '121.08', 'spread': '25.93', 'groupId': 'OG000'}, {'value': '109.93', 'spread': '20.79', 'groupId': 'OG001'}]}]}, {'title': 'FACT/GOG-Ntx total score-week 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '118.42', 'spread': '28.55', 'groupId': 'OG000'}, {'value': '113.43', 'spread': '12.80', 'groupId': 'OG001'}]}]}, {'title': 'FACT/GOG-Ntx total score-changes at week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '4.69', 'spread': '7.39', 'groupId': 'OG000'}, {'value': '3.21', 'spread': '18.40', 'groupId': 'OG001'}]}]}, {'title': 'FACT/GOG-Ntx total score-changes at week 9', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.02', 'spread': '8.01', 'groupId': 'OG000'}, {'value': '9.80', 'spread': '14.30', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '4 times within 9 weeks: at baseline (before the first treatment) and week 3, week 6, and week 9 during the protocol', 'description': 'The 27-item FACT-G evaluated the quality of life of patients undergoing cancer therapy over the past 7 days. The question is rated on a five-point scale, from 0 to 4 (0= not at all; 4= very much) and summed ( total score range= 0-108). An increase in scores represents an improvement in the overall quality of life.The 13-item Ntx subscale measures the severity and impact of neurotoxicity symptoms over the past seven days. Items are rated on a five-point scale, scored from 0 to 4 and summed ( total score range= 0-52). Higher scores on the neurotoxicity scale indicate improvements in neurotoxic symptoms.\n\nThe 40-item FACT/GOG-Ntx total score represents the sum of the FACT-G and Ntx subscale (total score range=0-160).The FACT/GOG-Ntx trial outcome index (TOI) contained the scores of the PWB, FWB, and FACT/GOG-Ntx subscale (total score range= 0-104).We analyzed the data (1) within group analysis(2) between group analysis(3) the changes between group analysis', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': '* In the acupuncture group, one subject withdrew from the trial because of needle phobia after the third week of treatment, and another subject withdrew from the trial because of cellulitis in the radiation treatment site after completing the sixth week of treatment\n* In the placebo group, one subject did not record the scoring result after completing the sixth week of acupuncture treatment because of the omission to fill in this scale'}, {'type': 'SECONDARY', 'title': 'World Health Organization Quality of Life Scale(WHOQOL)-BREF (Taiwan Version)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'The Acupuncture Group', 'description': ': Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), or Shenmen(HT7) for upper limbs. For plantar numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), or Zusanli(ST36) for lower limbs. If severe numbness occurred, Taixi(KI3) or Yongquan(K1) should be added for feet numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .'}, {'id': 'OG001', 'title': 'The Controlled Group', 'description': 'Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.'}], 'classes': [{'title': 'Physical health-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '60.80', 'spread': '15.97', 'groupId': 'OG000'}, {'value': '55.20', 'spread': '12.69', 'groupId': 'OG001'}]}]}, {'title': 'Physical health-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '60.88', 'spread': '17.88', 'groupId': 'OG000'}, {'value': '59.50', 'spread': '11.34', 'groupId': 'OG001'}]}]}, {'title': 'Physical health-Changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.63', 'spread': '13.52', 'groupId': 'OG000'}, {'value': '4.30', 'spread': '13.36', 'groupId': 'OG001'}]}]}, {'title': 'Psychological-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '51.40', 'spread': '13.79', 'groupId': 'OG000'}, {'value': '45.20', 'spread': '16.58', 'groupId': 'OG001'}]}]}, {'title': 'Psychological-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '55.50', 'spread': '18.62', 'groupId': 'OG000'}, {'value': '52.50', 'spread': '13.52', 'groupId': 'OG001'}]}]}, {'title': 'Psychological-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.13', 'spread': '11.79', 'groupId': 'OG000'}, {'value': '7.30', 'spread': '8.14', 'groupId': 'OG001'}]}]}, {'title': 'Social relationships-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '62.10', 'spread': '9.56', 'groupId': 'OG000'}, {'value': '54.50', 'spread': '10.22', 'groupId': 'OG001'}]}]}, {'title': 'Social relationships-post Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '68.00', 'spread': '11.15', 'groupId': 'OG000'}, {'value': '58.90', 'spread': '10.80', 'groupId': 'OG001'}]}]}, {'title': 'Social relationships-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.88', 'spread': '9.69', 'groupId': 'OG000'}, {'value': '4.40', 'spread': '11.90', 'groupId': 'OG001'}]}]}, {'title': 'Environment-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '61.90', 'spread': '8.20', 'groupId': 'OG000'}, {'value': '61.40', 'spread': '13.02', 'groupId': 'OG001'}]}]}, {'title': 'Environment-post Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '61.75', 'spread': '10.33', 'groupId': 'OG000'}, {'value': '66.30', 'spread': '11.84', 'groupId': 'OG001'}]}]}, {'title': 'Environment-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.63', 'spread': '11.60', 'groupId': 'OG000'}, {'value': '4.90', 'spread': '10.97', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'We measured 2 times within 9 weeks: before and after treatment', 'description': 'WHOQOL-BREF Taiwan version was validated to be a good clinical tool across five kinds of Taiwanese cancer survivors. There are a total 28 items by adding 2 additional items to account for Taiwanese cultural adaptations. Item scores range from 1 to 5 (1 =the worst condition; 5=the best condition), except for 3 items (Ph1, Ph2, and Ps6), which are reverse coded. Each domain in the scale can be translated into two ranges of domain scores (0-100 and 4-20), and we used 0-100 scale in this study. The Higher scores in each domain indicate the better quality of life for patients with cancers We analyzed the data (1) within group analysis: compared post-treatment with baseline. (2) between group analysis: compared the acupuncture group and sham acupuncture group at week 9. (3) the between group differences of the changes from post-treatment to baseline.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': '\\- In the acupuncture group, one subject withdrew from the trial because of needle phobia after the third week of treatment, and another subject withdrew from the trial because of cellulitis in the radiation treatment site after completing the sixth week of treatment'}, {'type': 'SECONDARY', 'title': 'Touch Test Sensory Evaluator', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'The Acupuncture Group', 'description': 'Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), or Shenmen(HT7) for upper limbs. For plantar numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), or Zusanli(ST36) for lower limbs. If severe numbness occurred, Taixi(KI3) or Yongquan(K1) should be added for feet numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .'}, {'id': 'OG001', 'title': 'The Controlled Group', 'description': 'Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.'}], 'classes': [{'title': 'LHT-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.64', 'spread': '1.87', 'groupId': 'OG000'}, {'value': '1.62', 'spread': '1.41', 'groupId': 'OG001'}]}]}, {'title': 'LHT-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.41', 'spread': '0.66', 'groupId': 'OG000'}, {'value': '1.82', 'spread': '2.28', 'groupId': 'OG001'}]}]}, {'title': 'LHT-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.54', 'spread': '2.12', 'groupId': 'OG000'}, {'value': '0.20', 'spread': '2.51', 'groupId': 'OG001'}]}]}, {'title': 'LHP-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.60', 'spread': '4.69', 'groupId': 'OG000'}, {'value': '1.98', 'spread': '2.89', 'groupId': 'OG001'}]}]}, {'title': 'LHP-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.25', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '1.44', 'spread': '1.99', 'groupId': 'OG001'}]}]}, {'title': 'LHP-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.92', 'spread': '5.20', 'groupId': 'OG000'}, {'value': '-0.54', 'spread': '1.73', 'groupId': 'OG001'}]}]}, {'title': 'RHT-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.52', 'spread': '1.35', 'groupId': 'OG000'}, {'value': '1.74', 'spread': '1.31', 'groupId': 'OG001'}]}]}, {'title': 'RHT-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.37', 'spread': '0.29', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '1.78', 'groupId': 'OG001'}]}]}, {'title': 'RHT-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.43', 'spread': '1.37', 'groupId': 'OG000'}, {'value': '-0.50', 'spread': '2.20', 'groupId': 'OG001'}]}]}, {'title': 'RHP-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.50', 'spread': '4.53', 'groupId': 'OG000'}, {'value': '1.91', 'spread': '1.85', 'groupId': 'OG001'}]}]}, {'title': 'RHP-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.28', 'spread': '0.20', 'groupId': 'OG000'}, {'value': '1.27', 'spread': '1.77', 'groupId': 'OG001'}]}]}, {'title': 'RHP-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.75', 'spread': '5.06', 'groupId': 'OG000'}, {'value': '-0.64', 'spread': '1.13', 'groupId': 'OG001'}]}]}, {'title': 'LFT-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '14.02', 'spread': '30.57', 'groupId': 'OG000'}, {'value': '10.30', 'spread': '17.99', 'groupId': 'OG001'}]}]}, {'title': 'LFT-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.50', 'spread': '2.49', 'groupId': 'OG000'}, {'value': '3.50', 'spread': '3.41', 'groupId': 'OG001'}]}]}, {'title': 'LFT-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-14.87', 'spread': '34.46', 'groupId': 'OG000'}, {'value': '-6.80', 'spread': '16.04', 'groupId': 'OG001'}]}]}, {'title': 'LFP-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '20.66', 'spread': '56.17', 'groupId': 'OG000'}, {'value': '9.61', 'spread': '18.09', 'groupId': 'OG001'}]}]}, {'title': 'LFP-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.35', 'spread': '5.13', 'groupId': 'OG000'}, {'value': '3.24', 'spread': '4.60', 'groupId': 'OG001'}]}]}, {'title': 'LFP-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-23.40', 'spread': '57.43', 'groupId': 'OG000'}, {'value': '-6.36', 'spread': '13.99', 'groupId': 'OG001'}]}]}, {'title': 'RFT-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.80', 'spread': '17.30', 'groupId': 'OG000'}, {'value': '5.28', 'spread': '7.55', 'groupId': 'OG001'}]}]}, {'title': 'RFT-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.43', 'spread': '2.94', 'groupId': 'OG000'}, {'value': '4.94', 'spread': '4.71', 'groupId': 'OG001'}]}]}, {'title': 'RFT-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-12.45', 'spread': '19.99', 'groupId': 'OG000'}, {'value': '-0.34', 'spread': '7.15', 'groupId': 'OG001'}]}]}, {'title': 'RFP-baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.46', 'spread': '6.53', 'groupId': 'OG000'}, {'value': '9.36', 'spread': '18.01', 'groupId': 'OG001'}]}]}, {'title': 'RFP-post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '2.87', 'spread': '5.06', 'groupId': 'OG000'}, {'value': '3.94', 'spread': '3.77', 'groupId': 'OG001'}]}]}, {'title': 'RFP-changes at post-Tx', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-4.93', 'spread': '6.11', 'groupId': 'OG000'}, {'value': '-5.41', 'spread': '15.95', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '2 times within 9 weeks: before and after treatment', 'description': "Measurements were performed using a set of 20 von Frey monofilaments(Semmes-Weinstein Von Frey Aesthesiometer, Stoelting Co. 620 Wheat Lane, Wood Dale, IL, U.S.A.), with evaluator size/target forces from 1.65/0.008 gto 6.65/300 g. Each monofilament was calibrated to a target force in grams (g) within a 5% standard deviation. Thresholds for categories of tactile perception were defined by the filament manufacturer as follows: normal ; diminished light touch; diminished protective sensation; loss of protective sensation; deep pressure sensation only . All tests were performed by an independent assessor who was unaware of the allocation of randomization. All the procedures followed the operation manual provided by the filament manufacturer. Measuring sites include: LHT(Left hand's middle fingertip);LHP(Left hand's palm);RHT(Right hand's middle fingertip);RHP(Right hand's palm);LFT(Left foot's big toe tip);LFP(Left foot's plantar);RFT(Right foot's big toe tip);RFP(Right foot's plantar)", 'unitOfMeasure': 'grams', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': '* In the acupuncture group, one subject withdrew from the trial because of needle phobia after the third week of treatment, and another subject withdrew from the trial because of cellulitis in the radiation treatment site after completing the sixth week of treatment\n* In the placebo group, one subject did not record the scoring result after completing the sixth week of acupuncture treatment because of the omission to fill in this scale'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Explore the Neuroprotective Mechanism of Acupuncture', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'The Acupuncture Group', 'description': 'Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), or Shenmen(HT7) for upper limbs. For plantar numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), or Zusanli(ST36) for lower limbs. If severe numbness occurred, Taixi(KI3) or Yongquan(K1) should be added for feet numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .'}, {'id': 'OG001', 'title': 'The Controlled Group', 'description': 'Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.'}], 'timeFrame': '2 times within 9 weeks: before and after treatment', 'description': '15 cc of blood samples will be drawn before and after 15 sessions of treatments from participants in both groups. The blood samples will be analyzed by enzyme-linked immunosorbent assay (ELISA) for tumor necrosis factor-alfa and interleukin- 6, interleukin-10 and brain-derived nuerotrophic factor to evaluate the differences in the inflammation state of peripheral nervous system within and between groups.', 'reportingStatus': 'POSTED', 'populationDescription': 'Due to the difficulty of the execution in the hospital, the execution was abandoned'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'The Acupuncture Group', 'description': 'Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), and Shenmen(HT7) for upper limbs. For palm numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), and Zusanli(ST36) for lower limbs. For the acupuncture points, Taixi(KI3) and Yongquan(K1) should be added for foot numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .\n\nacupuncture: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi\'s Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, LTD., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints'}, {'id': 'FG001', 'title': 'The Controlled Group', 'description': 'Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.\n\nacupuncture: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi\'s Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, Limited, Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'recruitmentDetails': '269 patients diagnosed with breast cancer were screened from June 2018 to July 2020. Of 61 potentially eligible patients, 20 (32.8%) were enrolled and randomized as 10 in the acupuncture group and 10 in the sham acupuncture group. 208 ineligible patients were excluded, and 41 patients declined to participate in our study.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'The Acupuncture Group', 'description': 'Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), and Shenmen(HT7) for upper limbs. For palm numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), and Zusanli(ST36) for lower limbs. For the acupuncture points, Taixi(KI3) and Yongquan(K1) should be added for foot numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .\n\nacupuncture: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi\'s Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, LTD., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints'}, {'id': 'BG001', 'title': 'The Controlled Group', 'description': 'Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.\n\nacupuncture: More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi\'s Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, LTD., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '47.10', 'spread': '11.07', 'groupId': 'BG000'}, {'value': '52.10', 'spread': '11.18', 'groupId': 'BG001'}, {'value': '49.60', 'spread': '11.13', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race and Ethnicity Not Collected', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'populationDescription': 'Race and Ethnicity were not collected from any participant.'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Taiwan', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}], 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Eastern Cooperative Group(ECOG) performance status', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}], 'categories': [{'title': 'Grade 0', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}]}, {'title': 'Grade 1', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'Grade: ECOG performance status 0: Fully active, able to carry on all pre-disease performance without restriction\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work\n2. Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours\n3. Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours\n4. Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair\n5. Dead', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2019-08-01', 'size': 882380, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2021-02-25T02:11', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': '1. The acupuncture group: Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), or Shenmen(HT7) for upper limbs. For plantar numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), or Zusanli(ST36) for lower limbs. If severe numbness occurred, Taixi(KI3) or Yongquan(K1) should be added for feet numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .\n2. The Controlled group: Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-06-27', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-01', 'completionDateStruct': {'date': '2020-10-10', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-01-17', 'studyFirstSubmitDate': '2018-08-08', 'resultsFirstSubmitDate': '2021-02-04', 'studyFirstSubmitQcDate': '2018-08-08', 'lastUpdatePostDateStruct': {'date': '2025-01-20', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-01-17', 'studyFirstPostDateStruct': {'date': '2018-08-10', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-01-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-10-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Explore the Neuroprotective Mechanism of Acupuncture', 'timeFrame': '2 times within 9 weeks: before and after treatment', 'description': '15 cc of blood samples will be drawn before and after 15 sessions of treatments from participants in both groups. The blood samples will be analyzed by enzyme-linked immunosorbent assay (ELISA) for tumor necrosis factor-alfa and interleukin- 6, interleukin-10 and brain-derived nuerotrophic factor to evaluate the differences in the inflammation state of peripheral nervous system within and between groups.'}], 'primaryOutcomes': [{'measure': 'The Average Pain Severity in the Brief Pain Inventory-Short Form(BPI-SF)', 'timeFrame': 'We measured the average pain severity 4 times within 9 weeks [at baseline (before the first treatment) and week 3, week 6, and week 9 during the protocol].', 'description': 'The average pain severity was chosen as the primary assessment as neuropathy symptoms based on its ability to detect neuropathic pain in cancer patients, as well as its use to assess CIPN symptoms in other controlled clinical trials.The BPI-SF assesses pain when responding to the questionnaire (right now) and at its worst, least, and average pain severity in the last 24 h. The items range from 0 to 10 (0 = no pain; 10 = worst pain). The higher the pain severity scores, the worse the degree of pain experienced by the patient. We analyzed the data (1) within group analysis: compared the data at week 6 with baseline, and the data at week 9 with baseline from each group. (2) between group analysis: compared the acupuncture group and sham acupuncture group at week 6 and week 9. (3) the between group differences of the changes from week 6 to baseline and from week 9 to baseline.'}], 'secondaryOutcomes': [{'measure': 'Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group- Neurotoxicity(FACT/GOG-NTX)-13', 'timeFrame': '4 times within 9 weeks: at baseline (before the first treatment) and week 3, week 6, and week 9 during the protocol', 'description': 'The 27-item FACT-G evaluated the quality of life of patients undergoing cancer therapy over the past 7 days. The question is rated on a five-point scale, from 0 to 4 (0= not at all; 4= very much) and summed ( total score range= 0-108). An increase in scores represents an improvement in the overall quality of life.The 13-item Ntx subscale measures the severity and impact of neurotoxicity symptoms over the past seven days. Items are rated on a five-point scale, scored from 0 to 4 and summed ( total score range= 0-52). Higher scores on the neurotoxicity scale indicate improvements in neurotoxic symptoms.\n\nThe 40-item FACT/GOG-Ntx total score represents the sum of the FACT-G and Ntx subscale (total score range=0-160).The FACT/GOG-Ntx trial outcome index (TOI) contained the scores of the PWB, FWB, and FACT/GOG-Ntx subscale (total score range= 0-104).We analyzed the data (1) within group analysis(2) between group analysis(3) the changes between group analysis'}, {'measure': 'World Health Organization Quality of Life Scale(WHOQOL)-BREF (Taiwan Version)', 'timeFrame': 'We measured 2 times within 9 weeks: before and after treatment', 'description': 'WHOQOL-BREF Taiwan version was validated to be a good clinical tool across five kinds of Taiwanese cancer survivors. There are a total 28 items by adding 2 additional items to account for Taiwanese cultural adaptations. Item scores range from 1 to 5 (1 =the worst condition; 5=the best condition), except for 3 items (Ph1, Ph2, and Ps6), which are reverse coded. Each domain in the scale can be translated into two ranges of domain scores (0-100 and 4-20), and we used 0-100 scale in this study. The Higher scores in each domain indicate the better quality of life for patients with cancers We analyzed the data (1) within group analysis: compared post-treatment with baseline. (2) between group analysis: compared the acupuncture group and sham acupuncture group at week 9. (3) the between group differences of the changes from post-treatment to baseline.'}, {'measure': 'Touch Test Sensory Evaluator', 'timeFrame': '2 times within 9 weeks: before and after treatment', 'description': "Measurements were performed using a set of 20 von Frey monofilaments(Semmes-Weinstein Von Frey Aesthesiometer, Stoelting Co. 620 Wheat Lane, Wood Dale, IL, U.S.A.), with evaluator size/target forces from 1.65/0.008 gto 6.65/300 g. Each monofilament was calibrated to a target force in grams (g) within a 5% standard deviation. Thresholds for categories of tactile perception were defined by the filament manufacturer as follows: normal ; diminished light touch; diminished protective sensation; loss of protective sensation; deep pressure sensation only . All tests were performed by an independent assessor who was unaware of the allocation of randomization. All the procedures followed the operation manual provided by the filament manufacturer. Measuring sites include: LHT(Left hand's middle fingertip);LHP(Left hand's palm);RHT(Right hand's middle fingertip);RHP(Right hand's palm);LFT(Left foot's big toe tip);LFP(Left foot's plantar);RFT(Right foot's big toe tip);RFP(Right foot's plantar)"}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['acupuncture', 'chemotherapy-induced peripheral neuropathy'], 'conditions': ['Randomized Controlled Trial', 'Breast Cancer', 'Chemotherapy-induced Peripheral Neuropathy', 'Acupuncture']}, 'referencesModule': {'references': [{'pmid': '23983788', 'type': 'BACKGROUND', 'citation': 'Franconi G, Manni L, Schroder S, Marchetti P, Robinson N. A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy. Evid Based Complement Alternat Med. 2013;2013:516916. doi: 10.1155/2013/516916. Epub 2013 Jul 24.'}, {'pmid': '24590861', 'type': 'BACKGROUND', 'citation': 'Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37. doi: 10.3322/caac.21204.'}, {'pmid': '27013473', 'type': 'RESULT', 'citation': 'Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res Treat. 2016 Apr;156(3):453-464. doi: 10.1007/s10549-016-3759-2. Epub 2016 Mar 25.'}, {'pmid': '27130723', 'type': 'RESULT', 'citation': 'Wong R, Major P, Sagar S. Phase 2 Study of Acupuncture-Like Transcutaneous Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy. Integr Cancer Ther. 2016 Jun;15(2):153-64. doi: 10.1177/1534735415627926. Epub 2016 Apr 29.'}], 'seeAlsoLinks': [{'url': 'https://www.ncbi.nlm.nih.gov/pubmed/27013473', 'label': 'pubmed'}, {'url': 'https://www.ncbi.nlm.nih.gov/pubmed/27130723', 'label': 'pubmed'}, {'url': 'https://www.ncbi.nlm.nih.gov/pubmed/23983788', 'label': 'pubmed'}, {'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24590861', 'label': 'pubmed'}]}, 'descriptionModule': {'briefSummary': "Peripheral neuropathy is currently the second most common side effect after chemotherapy, second only to the side effects of blood toxicity. A variety of chemotherapy drugs may induce peripheral neurotoxicity and cause by the cumulative dose of chemotherapy drugs. Symptoms include sensory paresthesia, feeling dullness or numbness, glove-like feeling distributed in the palm. The currently most effective way is to interrupt the treatment or adjust the dose of chemotherapeutic drugs, but it is easy to make patients discontinue chemotherapy. The purpose of this study is to explore the impact of acupuncture on neurological symptoms and quality of life. Three kinds of questionnaires will be used:(1) Brief pain inventory- short form to assess the extent of pain, and the impact of daily life. (2) the Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group- Neurotoxicity(FACT/GOG-NTX)-13 (Version 4) to assess changes in neurological symptoms; (3) World Health Organization Quality of Life Scale-(WHOQOL-BREF) to assess changes in the quality of life of patients. The course of treatment was evaluated for nine weeks. Changes in neurological function and quality of life will be evaluated before treatment, the third week of treatment, the sixth week of treatment, till the ninth week. The aim of this study is to confirm that acupuncture can improve peripheral neuropathy after chemotherapy, in order to enhance breast cancer patients' quality of life, and provide the new opportunity for integrative therapy between Chinese and Western medicine.\n\nKeywords：acupuncture , chemotherapy-induced peripheral neuropathy", 'detailedDescription': '(I) Background of the research A variety of neurotoxic chemotherapeutic agents, including platinums (e.g. cisplatin, carboplatin, and oxaliplatin), taxanes (e.g. paclitaxel and docetaxel), and vinca alkaloids (e.g. vincristine and vinblastine), thalidomide and bortezomib, may induce peripheral neuropathy. Generally speaking, sensory nerve dysfunction is more common than motor involvement. It causes hands and feet to feel tingling, dullness or numbness symmetrically, which will be a glove-like ("glove-and-stocking type") sensation distributed in palms and soles. Patient\'s touch, vibration, and proprioception senses may be impaired under clinical examinations.\n\nchemotherapy-induced peripheral neuropathy(CIPN) relates to the cumulative doses of chemotherapeutic agents. Sometimes, when chemotherapy is stopped, neuropathy symptoms may continue or worsen, which is called a "costing phenomenon". Nerve damaging usually starts from ends of the extremities, while individual doses were accumulated, it gradually extends to proximal joints or ganglions. CIPN is currently the second most common side, next to hematotoxicity. Within thirty days after chemotherapy, 68.1% of patients may develop CIPN, most of which can be relieved or improved, but there are still 30-83% symptoms persist over 6 months.\n\nAt present, the most effective way to treat CIPN is to stop the treatment protocol or adjust doses of chemotherapy; however, it affects the effect of chemotherapy in degrading tumor growth. Plenty of pharmacological or non-pharmacological treatments are still under investigation, such as antioxidant medication (e.g. Acetyl-L-carnitine, glutamine, vit B12, fish oil, etc.), anxiolytics (e.g. venlafaxine), neuroprotective agents (e.g. infusion of calcium ions, magnesium ions), food supplements, acupuncture, light stimulation, etc. Acupuncture with the advantages of clinically effective, easy-practice and relatively safe, few studies revealed its effect on CIPN, however, there is still a lack of large clinical trials to evaluate its effectiveness.\n\n(ii) Purpose of the research To investigate the efficacy of acupuncture on peripheral neuropathy after chemotherapy administration in patients with breast cancer.\n\n(iii) Importance of the research Current studies revealed that acupuncture might be effective on CIPN, however, insufficient number of participants or lack of control groups limit the quality of clinical studies. Therefore, the aim of our study to conduct a randomized controlled clinical trial to evaluate the efficacy of acupuncture on peripheral neuropathy caused by chemotherapy.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'The inclusion criteria will be: female more than 20 years of age; breast cancer with early stage at I-III; had completed chemotherapy; the neurotoxic chemotherapeutic agents included taxanes, platinums, or others; less than grade three in the Eastern Cooperative Oncology Group (ECOG) status; higher than grade one in National Cancer Institute-common terminology criteria for adverse events(NCI-CTCAE) scale.\n\nThe exclusion criteria will be: having less than three months in mean survival time, history of diabetic neuropathy before chemotherapy administration, history of other preexisting peripheral neuropathy, other inflammatory or metabolic arthritis, severe blood coagulation diseases or with latent bleeding tendency, unstable cardiovascular diseases, or other preexisting muscle-skeletal diseases.'}, 'identificationModule': {'nctId': 'NCT03626220', 'briefTitle': 'Acupuncture on Chemotherapy-induced Peripheral Neuropathy', 'organization': {'class': 'OTHER', 'fullName': 'China Medical University Hospital'}, 'officialTitle': 'Evaluation the Efficacy of Acupuncture in Chemotherapy Induced Peripheral Neuropathy', 'orgStudyIdInfo': {'id': 'CMUH106-REC2-117'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'The acupuncture group', 'description': 'Acupuncture treatment will be performed for 9 weeks. Acupuncture treatment will be performed for 9 weeks. The frequency of acupuncture will be twice a week for the first six weeks, and once a week for the following three weeks. 30 minutes needling at each treatment. Acupuncture points include Baihui(GV20), Qihai(CV6), Quchi(LI11), Hegu(LI4), Neiguan(P6), or Shenmen(HT7) for upper limbs. For plantar numbness, choose two acupoints to use in turn; use Weizhong(BL40), Sanyinjiao(SP6), or Zusanli(ST36) for lower limbs. If severe numbness occurred, Taixi(KI3) or Yongquan(K1) should be added for feet numbness. "De qi" sensation, such as soreness, numbness, pain, etc. will be achieved at each acupoints .', 'interventionNames': ['Other: acupuncture']}, {'type': 'SHAM_COMPARATOR', 'label': 'The controlled group', 'description': 'Acupuncture with superficial needling 0.5 cun (estimated 1cm with deviation depends on the body size of each participants) away from the acupoints, which only superficially penetrated the skin without feeling of "De Qi" sensation.', 'interventionNames': ['Other: acupuncture']}], 'interventions': [{'name': 'acupuncture', 'type': 'OTHER', 'description': "More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi's Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, Limited., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints", 'armGroupLabels': ['The acupuncture group', 'The controlled group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '709', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'An Nan Hospital, China Medical University', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}], 'overallOfficials': [{'name': 'Chien-Chen Huang, M.S.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'An Nan Hospital, China Medical University, Tainan, Taiwan, R.O.C.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'China Medical University Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Attending physician', 'investigatorFullName': 'Chien-Chen Huang', 'investigatorAffiliation': 'China Medical University Hospital'}}}}